Black Diamond Therapeutics Announces Promotion of Melanie Morrison to Chief Development Officer
13 June 2023 - 10:00PM
Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a clinical-stage
precision oncology medicine company developing MasterKey therapies
designed to overcome limitations of existing therapies by targeting
families of oncogenic driver mutations in patients with genetically
defined cancers, today announced the promotion of Melanie Morrison
from Senior Vice President, Development Operations to Chief
Development Officer. As Chief Development Officer, Ms. Morrison
leads the Company’s clinical operations, program management and
program leadership functions, and regulatory affairs.
“Since joining the Company in 2022 as Senior Vice President,
Development Operations, Melanie has demonstrated exceptional
leadership and has played a critical role in advancing our clinical
programs by leveraging her expertise in clinical-stage oncology
development, operations and regulatory affairs. She has played an
integral part in our Phase 1 trial for BDTX-1535 in non-small cell
lung cancer and glioblastoma and I am extremely pleased to announce
her well-deserved promotion to Chief Development Officer. I look
forward to continuing to work with her alongside the rest of the
executive leadership team as we move towards the initial clinical
data update from the Phase 1 trial of BDTX-1535,” said David M.
Epstein, Ph.D., President and Chief Executive Officer of Black
Diamond Therapeutics.
“The passion of the Black Diamond team is evidenced by their
commitment to driving novel MasterKey inhibitors into the clinic
for patients who are in serious need of new treatment options. I am
excited to continue supporting the Company’s mission in this new
role, as we work to overcome the limitations of existing therapies
and fulfill the promise of precision oncology,” said Ms.
Morrison.
Ms. Morrison joined Black Diamond in October 2022 with over two
decades of experience in clinical operations, program management,
product leadership and other key development functions in addition
to driving corporate transitions from early to late-stage
development at several biopharmaceutical companies. Prior to Black
Diamond, Ms. Morrison was Senior Vice President, Program Management
and Clinical Operations at Nuvation Bio, a clinical-stage oncology
company, where she built and oversaw multiple groups within the
development organization in support of Nuvation Bio’s pipeline.
Previously she held program and clinical operations leadership
roles at Aduro Biotech, Immune Design, and Medivation, where, prior
to its acquisition by Pfizer, she was Vice President, Clinical
Operations. Earlier in her career, Ms. Morrison held roles of
increasing responsibility within the clinical operations and
project management teams at Genentech focused on its oncology
pipeline. She holds a Master of Science in Health Sciences from The
George Washington University School of Medicine and Health Sciences
and a Bachelor of Science from University of California, Davis.
About Black Diamond
Black Diamond Therapeutics is a clinical-stage precision
oncology medicine company focused on the development of MasterKey
therapies that target families of oncogenic mutations in clinically
validated targets. Black Diamond leverages a deep understanding of
cancer genetics and onco-protein structure and function, to
discover and develop innovative MasterKey therapies. The Company’s
MasterKey therapies are designed to overcome resistance, minimize
on-target, wild-type mediated toxicities, and be brain-penetrant to
address significant unmet medical needs of patients with
genetically defined cancers. The Company is advancing a robust
pipeline with lead clinical-stage program BDTX-1535, targeting
MasterKey mutations in both EGFR mutant-positive NSCLC and in GBM,
and BDTX-4933, a program targeting RAF MasterKey mutations in solid
tumors, as well as discovery-stage research programs. The Company’s
proprietary MAP drug discovery engine is designed to allow Black
Diamond to analyze population-level genetic sequencing tumor data
and validate MasterKey mutations. For more information, please
visit www.blackdiamondtherapeutics.com.
Forward-Looking StatementsStatements contained
in this press release regarding matters that are not historical
facts are “forward-looking statements” within the meaning of the
Private Securities Litigation Reform Act of 1995. Because such
statements are subject to risks and uncertainties, actual results
may differ materially from those expressed or implied by such
forward-looking statements. Such statements include, but are not
limited to, statements regarding: the continued development and
advancement of BDTX-1535 and the Company’s other development
programs, including the ongoing Phase 1 clinical trial of BDTX-1535
and the expected timing for data updates for BDTX-1535. Any
forward-looking statements in this statement are based on
management’s current expectations of future events and are subject
to a number of risks and uncertainties that could cause actual
results to differ materially and adversely from those set forth in
or implied by such forward-looking statements. Risks that
contribute to the uncertain nature of the forward-looking
statements include those risks and uncertainties set forth in its
Annual Report on Form 10-K for the year ended December 31, 2022,
filed with the United States Securities and Exchange Commission and
in its subsequent filings filed with the United States Securities
and Exchange Commission. All forward-looking statements contained
in this press release speak only as of the date on which they were
made. The Company undertakes no obligation to update such
statements to reflect events that occur or circumstances that exist
after the date on which they were made.
Contact:Julie Seidel, Stern Investor
Relations(212) 362-1200investors@bdtx.commedia@bdtx.com
Black Diamond Therapeutics (NASDAQ:BDTX)
Historical Stock Chart
From Apr 2024 to May 2024
Black Diamond Therapeutics (NASDAQ:BDTX)
Historical Stock Chart
From May 2023 to May 2024